Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort.
Richters A, Robbrecht DGJ, Meijer RP, van der Heijden AG, Kiemeney LALM, van den Bosch J, Suelmann BBM, Özdemir BC; ProBCI Study Group; Mehra N, Aben KKH. Richters A, et al. Among authors: robbrecht dgj. Eur Urol Open Sci. 2023 Dec 20;59:50-54. doi: 10.1016/j.euros.2023.11.010. eCollection 2024 Jan. Eur Urol Open Sci. 2023. PMID: 38213646 Free PMC article.
[Symptomatic hypocalcaemia on denosumab use].
Baptista Lopes V, Robbrecht D, van Thiel S, van Guldener C. Baptista Lopes V, et al. Ned Tijdschr Geneeskd. 2013;157(29):A6159. Ned Tijdschr Geneeskd. 2013. PMID: 23859106 Dutch.
[Mesenteric panniculitis: variable presentations].
Robbrecht DG, Alidjan F, Eikemans B, Haans DA, van Guldener C, van Wijngaarden P. Robbrecht DG, et al. Ned Tijdschr Geneeskd. 2012;155(25):A4555. Ned Tijdschr Geneeskd. 2012. PMID: 22748362 Dutch.
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
Vermunt MAC, Robbrecht DGJ, Devriese LA, Janssen JM, Thijssen B, Keessen M, van Eijk M, Kessels R, Eskens FALM, Beijnen JH, Mehra N, Bergman AM. Vermunt MAC, et al. Among authors: robbrecht dgj. Cancer Rep (Hoboken). 2021 Aug;4(4):e1367. doi: 10.1002/cnr2.1367. Epub 2021 Mar 12. Cancer Rep (Hoboken). 2021. PMID: 33709626 Free PMC article. Clinical Trial.
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW. van der Wijngaart H, et al. Among authors: robbrecht dgj. Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475104
Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC, van Gennep EJ, Kiemeney LALM, Witjes JA, Voskuilen CS, Deelen M, Mertens LS, Meijer RP, Boormans JL, Robbrecht DGJ, Beerepoot LV, Verhoeven RHA, Ripping TM; BlaZIB Study Group; van Rhijn BWG, Aben KKH, Hermans TJN. van Hoogstraten LMC, et al. Among authors: robbrecht dgj. World J Urol. 2022 Jan;40(1):111-118. doi: 10.1007/s00345-021-03839-7. Epub 2021 Sep 28. World J Urol. 2022. PMID: 34585294 Free PMC article.
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
Stockem CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, van Montfoort ML, Balduzzi S, Boormans JL, Franckena M, Meijer RP, Robbrecht DGJ, Suelmann BBM, Schaake EE, van der Heijden MS. Stockem CF, et al. Among authors: robbrecht dgj. Front Oncol. 2023 Aug 29;13:1246603. doi: 10.3389/fonc.2023.1246603. eCollection 2023. Front Oncol. 2023. PMID: 37711193 Free PMC article.
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Rijnders M, Nakauma-González JA, Robbrecht DGJ, Gil-Jimenez A, Balcioglu HE, Oostvogels AAM, Aarts MJB, Boormans JL, Hamberg P, van der Heijden MS, Szabados BE, van Leenders GJLH, Mehra N, Voortman J, Westgeest HM, de Wit R, van der Veldt AAM, Debets R, Lolkema MP. Rijnders M, et al. Among authors: robbrecht dgj. Nat Commun. 2024 Feb 14;15(1):1349. doi: 10.1038/s41467-024-45714-0. Nat Commun. 2024. PMID: 38355607 Free PMC article.
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer.
Rijnders M, Robbrecht DGJ, Oostvogels AAM, van Brakel M, Boormans JL, Aarts MJB, Balcioglu HE, Hamberg P, Voortman J, Westgeest HM, Lolkema MP, de Wit R, van der Veldt AAM, Debets R. Rijnders M, et al. Among authors: robbrecht dgj. Cancer Immunol Immunother. 2023 Mar;72(3):759-767. doi: 10.1007/s00262-022-03250-0. Epub 2022 Aug 17. Cancer Immunol Immunother. 2023. PMID: 35976415 Free PMC article.
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.
Mendelaar PAJ, Robbrecht DGJ, Rijnders M, de Wit R, de Weerd V, Deger T, Westgeest HM, Aarts MJB, Voortman J, Martens JWM, van der Veldt AAM, Nakauma-González JA, Wilting SM, Lolkema M. Mendelaar PAJ, et al. Among authors: robbrecht dgj. Mol Oncol. 2022 May;16(10):2086-2097. doi: 10.1002/1878-0261.13196. Epub 2022 Mar 17. Mol Oncol. 2022. PMID: 35181986 Free PMC article.
26 results